A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00073489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2011-10-17
Summary
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients.
Conditions
Interventions
- DRUG
-
OSI-461
Sponsors & Collaborators
-
OSI Pharmaceuticals
collaborator INDUSTRY -
Astellas Pharma Inc
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-05-31
- Completion
- 2003-12-31
Countries
- United States
Study Locations
More Related Trials
-
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
NCT02157324 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01868893 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00496132 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436 ·Status: RECRUITING ·Phase: PHASE2
-
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
NCT00003635 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia
NCT00003861 ·Status: ACTIVE_NOT_RECRUITING
-
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786 ·Status: TERMINATED ·Phase: PHASE1
-
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04434196 ·Status: COMPLETED ·Phase: PHASE1
-
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
NCT04722172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
NCT00512083 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00536341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL
NCT03502876 ·Status: COMPLETED
-
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
NCT01703364 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
NCT01732861 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia
NCT04699162 ·Status: COMPLETED
-
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
NCT05975164 ·Status: UNKNOWN
-
Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
NCT01363297 ·Status: COMPLETED ·Phase: PHASE2
-
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
NCT02053610 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
NCT01133743 ·Status: COMPLETED ·Phase: PHASE2
-
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
NCT00464633 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
NCT02042911 ·Status: COMPLETED ·Phase: PHASE2